Last $21.04 USD
Change Today +0.08 / 0.38%
Volume 228.4K
CBM On Other Exchanges
Symbol
Exchange
New York
Berlin
As of 8:04 PM 04/17/14 All times are local (Market data is delayed by at least 15 minutes).

cambrex corp (CBM) Snapshot

Open
$20.83
Previous Close
$20.96
Day High
$21.18
Day Low
$20.57
52 Week High
02/18/14 - $22.34
52 Week Low
05/1/13 - $11.75
Market Cap
641.4M
Average Volume 10 Days
316.7K
EPS TTM
$0.87
Shares Outstanding
30.5M
EX-Date
05/4/07
P/E TM
24.2x
Dividend
--
Dividend Yield
--
Current Stock Chart for CAMBREX CORP (CBM)

Related News

No related news articles were found.

cambrex corp (CBM) Related Businessweek News

No Related Businessweek News Found

cambrex corp (CBM) Details

Cambrex Corporation, a life sciences company, provides various products and services for the development and commercialization of new and generic therapeutics worldwide. Its products consist of active pharmaceutical ingredients and pharmaceutical intermediates that are used in the production of prescription and over-the-counter drug products, as well as other fine chemicals. The company serves generic drug companies, and companies that discover and commercialize new small molecule human therapeutics using organic chemistry. The company sells its products directly, as well as through independent agents. Cambrex Corporation was founded in 1981 and is headquartered in East Rutherford, New Jersey.

936 Employees
Last Reported Date: 02/11/14
Founded in 1981

cambrex corp (CBM) Top Compensated Officers

Chief Executive Officer, President and Direct...
Total Annual Compensation: $533.3K
Chief Financial Officer, Principal Accounting...
Total Annual Compensation: $400.0K
Chief Operating Officer and Executive Vice Pr...
Total Annual Compensation: $412.5K
Managing Director of Cambrex Profarmaco Milan...
Total Annual Compensation: $338.7K
Compensation as of Fiscal Year 2013.

cambrex corp (CBM) Key Developments

Cambrex Corporation. Presents at 13th Annual Needham Healthcare Conference, Apr-09-2014 04:20 PM

Cambrex Corporation. Presents at 13th Annual Needham Healthcare Conference, Apr-09-2014 04:20 PM. Venue: The Westin Grand Central Hotel, New York, New York, United States. Speakers: Steven M. Klosk, Chief Executive Officer, President and Director.

Cambrex Corporation Reports Unaudited Consolidated Earnings Results for the Fourth Quarter and Full Year Ended December 31, 2013; Provides Consolidated Earnings Guidance for the Full Year 2014

Cambrex Corporation reported unaudited consolidated earnings results for the fourth quarter and full year ended December 31, 2013. For the quarter, net sales were $102,435,000 against $69,658,000 a year ago. Sales were 46.3% higher compared to the same period last year. The increase was primarily due to higher sales of a recently approved branded active pharmaceutical ingredient and controlled substances, partially offset by lower sales of generic and branded APIs and products utilizing the Company's drug delivery technology. Net revenues were $103,036,000 against $69,930,000 a year ago. Operating profit was $16,384,000 against $7,417,000 a year ago. The increase in operating profit was primarily the result of higher gross profit partially offset by higher SG&A expenses. Income before income taxes was $15,077,000 against $6,312,000 a year ago. Income from continuing operations was $9,440,000 or $0.30 per diluted share against $44,242,000 or $1.44 per diluted share a year ago. Net income was $8,899,000 or $0.29 per diluted and basic share against $43,648,000 or $1.42 per diluted share a year ago. EBITDA was $22,226,000 against $13,058,000 a year ago. Capital expenditures and depreciation were $9.6 million and $5.8 million, respectively, compared to $17.2 million and $5.6 million in the same period last year. For the year, net sales were $315,861,000 against $275,428,000 a year ago. Net revenues were $318,176,000 against $276,501,000 a year ago. Operating profit was $49,629,000 against $35,695,000 a year ago. Income before income taxes was $45,007,000 against $31,368,000 a year ago. Income from continuing operations was $30,275,000 or $0.98 per diluted share against $63,229,000 or $2.09 per diluted share a year ago. Net income was $25,915,000 or $0.84 per diluted and basic share against $62,303,000 or $2.06 per diluted share a year ago. Adjusted operating profit was $44,949,000 against $35,695,000 a year ago. Adjusted EBITDA was $67,422,000 against $57,470,000 a year ago. Adjusted income from continuing operations was $30,587,000 or $0.99 per share against $24,416,000 or $0.81 per share a year ago. The company currently expects that full year 2014 sales, excluding the impact of foreign currency, will increase between 8% and 12% over 2013, and that full year 2014 EBITDA will be between $70 million and $76 million. The company expects that 2014 adjusted income from continuing operations will be between $0.99 and $1.10 per share. Based on current expectations regarding the timing of orders, the Company expects 2014 to start off slowly, with most of the anticipated growth coming from the second quarter and thereafter. The company estimates that its 2014 consolidated effective tax rate will be between 33% and 37%. Capital expenditures for 2014 are expected to be approximately $35 million to $39 million and depreciation is expected to be $25 million to $27 million in 2014. During 2014, the company also expects to spend approximately $2 million in R&D expense to co-develop one or more generic finished dosage form drug product, with one or more generic drug company partners. The company expects 2014 to be a very positive year for cash flow, and therefore expect to see debt, net of cash, improve by between $25 million and $30 million during 2014. The company expects depreciation to be between $25 million and $27 million for 2014, at the midpoint, a $3.8 million increase over 2013.

Cambrex Corporation., Q4 2013 Earnings Call, Feb 11, 2014

Cambrex Corporation., Q4 2013 Earnings Call, Feb 11, 2014

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
CBM:US $21.04 USD +0.08

CBM Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Aceto Corp $21.46 USD +0.19
Biocon Ltd 454.75 INR 0.00
Cipla Ltd/India 400.70 INR 0.00
Piramal Enterprises Ltd 606.20 INR 0.00
Produits Chimiques Auxiliaires et de Synthese €4.53 EUR -0.05
View Industry Companies
 

Industry Analysis

CBM

Industry Average

Valuation CBM Industry Range
Price/Earnings 21.5x
Price/Sales 2.0x
Price/Book 3.1x
Price/Cash Flow 24.9x
TEV/Sales 1.7x
 | 

Post a JobJobs

View all jobs

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact CAMBREX CORP, please visit www.cambrex.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.